Registration - In-house Corporation

Subject Matters

• Aboriginal Affairs
• Budget
• Consumer Issues
• Defence
• Health
• Industry
• Intellectual Property
• International Trade
• Research and Development
• Science and Technology
• Taxation and Finance

Subject Matter Details

Legislative Proposal, Bill or Resolution, Regulation

• Food and Drugs Act & Regulations with respect to Drug Export Restrictions and international trade.
• The Controlled Drugs & Substances Act with respect to regulatory requirements relevant to opioid medication (e.g., Section 56 exemption to prescribe methadone) in order to address barriers to accessing opioid dependence treatment in Canada.
• The Food and Drugs Act and Regulations with respect to their impact on addiction treatments.

Policies or Program

• A national pharmacare strategy with respect to the need for full coverage/reimbursement of opioid dependence treatments and addiction treatments.
• Common Drug Review with respect to reimbursement decisions and the approval process.
• Correctional Services Canada with regards to the accessibility of opioid dependence treatments for inmates in federal correctional facilities.
• Coverage of opioid dependence treatments and addiction treatments with respect to Canadian Forces returning to Canada from active duty overseas.
• Government of Canada Drug Plans, with respect to the reimbursement of therapeutic products for relevant beneficiaries.
• Non-Insured Health Benefits under Health Canada with regards to reimbursement criteria of opioid dependence & addiction treatments for First Nations, Inuit and Metis in Canada.
• The National Anti-Drug Strategy with respect to public relations and awareness programs relating to addiction and opioid dependence.
• The federal Science & Technology Strategy and/or any federal Government policy or program initiatives to support Research and Development in Canada, and advocate for the development of a pharmaceutical sectoral strategy in support of more research & development in Canada
• The national prescription drug abuse strategy, "First Do No Harm: Responding to Canada's Prescription Drug Crisis" with respect to risk mitigation strategies for the pharmaceutical industry to ensure high quality patient care, reform of the drug approval process in Canada and the launch of a national prescription drug monitoring and surveillance system.

Regulation

• Health Canada's ongoing review of naloxone's status on the Prescription Drug List, with respect to making it available without prescription.
• Patented Medicine Prices Review Board (PMPRB) Regulations as it relates to reporting requirements and pricing guidelines.
• Patented Medicines Regulations (Notice of Compliance) with respect to regulating intellectual property for therapeutic products

Communication Techniques

• Written communication
• Oral communication
• Participation in Industry Associations and delegations

Government Institutions

• Canadian Institutes of Health Research (CIHR)
• Correctional Service of Canada (CSC)
• Finance Canada (FIN)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Indigenous and Northern Affairs Canada
• Innovation, Science and Economic Development Canada (ISED)
• Justice Canada (JC)
• National Defence (DND)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Privy Council Office (PCO)
• Public Safety Canada (PS)
• Royal Canadian Mounted Police (RCMP)
• Senate of Canada
• Veterans Affairs Canada (VAC)

Address:
2 Gurdwara Road
Suite 512
Ottawa, ON  K2E 1A2
Canada

Telephone number: 613-274-4064
Fax number: 613-274-2856  

Parent Company Information